![]() Please Contact Us and see About Items That Can’t Be Returned. In some circumstances, these items may be eligible for a refund or a replacement (for example, if you receive the wrong item due to an Amazon AU error or if the item is faulty). In some cases, the nature of the item means that it is non-returnable, for example, due to hygiene/health and personal care/wellness/consumable nature of the product. Shamsinar said GSK aimed to expand its production to include Dequadin and antacid brand Tums by next year.You can return most new, unopened items fulfilled by Amazon AU within 30 days of receipt of delivery for a replacement or full refund of the price you paid for the item if you change your mind - see About Replacements and About Refunds. ![]() GSK’s local plant currently manufactures the Panadol range, Eno, Eye-mo and Oxy whereas products such as Ribena and Scott’s Emulsion are contract manufactured by local producers. Within its stable of products are many popular household brands, such as Panadol, Eno, Eye-Mo, Ribena, Oxy, Scott’s Emulsion, Horlicks and Zentel. GSK has in its more than 40 years in Malaysia invested about RM200mil in its operations. GSK Pharmaceutical Malaysia managing director David Franklin said despite a slower global economy, the demand for pharmaceutical products would increase because of the higher life expectancy and increased expectations among consumers. It spends about 14% of its annual sales in research and development, spending US$3.6bil last year against US$26bil in sales. He said GSK, the market leader of four out of five largest therapeutic categories, has about 6.8% share of the global pharmaceutical industry. Schlosser said GSK’s strength lay in its people and its culture, its trusted brands and quality of products, which lived up to its global quest “to improve the quality of human life by enabling people to do more, feel better and live longer.” Meanwhile, Sterling Drug (M) Sdn Bhd – GSK’s regional manufacturing hub for consumer healthcare products – expects RM15mil in exports to other GSK companies in Asia Pacific, its global manufacturing and supply site director, Shamsinar Shaari said.Ībout 37% of the products produced in the company’s plant at Ulu Kelang Industrial Estate, Kuala Lumpur (which is the largest over-the-counter plant in the country), are exported to 13 countries throughout Asia Pacific and the remainder distributed in Malaysia. The two companies, together with Sterling Drug (M) Sdn Bhd, collectively formed GSK Malaysia, following a global merger between Glaxo Wellcome and SmithKline Beecham early this year. GlaxoSmithKline Consumer Healthcare Sdn Bhd (formerly known as SmithKline Beecham Sdn Bhd) was expected to generate RM210mil of the sales and GlaxoSmithKline Pharmaceutical Sdn Bhd (formerly known as Glaxo Wellcome (M) Sdn Bhd) the remaining RM140mil, Schlosser told reporters in Kuala Lumpur yesterday. LEADING pharmaceutical and healthcare producer GlaxoSmithKline (GSK) expects its sales in Malaysia to grow by 5% to RM350mil this year, its consumer healthcare managing director and vice-president, East Asia, Jean Michel Schlosser said. Malaysian Society of Pharmaceutical Technology (MSPT)Ĭommonwealth Pharmaceutical Association (CPA) Malaysian Pharmacy Students Association (MyPSA) Chapter Health Technologies, Devices & Innovation Chapter ![]() Legislation / Jurisprudence Committee (include RUU)Ĭontinuing Professional Development Chapter MPS Registration with Registry of SocietyĪnnual General Meeting Organising Committee Code of Ethics for Pharmacists ( Pharmacy Board of Malaysia) ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |